PRMT3 Antibody

What is PRMT3 and why is it important in biomedical research?

PRMT3 (Protein arginine N-methyltransferase 3, also known as HRMT1L3) is a type I methyltransferase that catalyzes both monomethylation and asymmetric dimethylation of arginine residues in target proteins. PRMT3 is unique among the PRMT family due to its C2H2 zinc finger domain crucial for substrate recognition and its predominant cytoplasmic localization under physiological conditions .

PRMT3 is increasingly important in research because:

• It regulates critical biological processes including gene expression, retinoic acid synthesis, and signaling pathways

• It has been implicated in several cancers, with elevated expression correlating with poor prognosis

• It contributes to therapeutic resistance in multiple cancer types

• It plays roles in metabolic reprogramming, particularly glycolysis in cancer cells

• It mediates immune evasion through various mechanisms

What types of PRMT3 antibodies are available for research, and how do they differ in applications?

Based on the search results, several types of PRMT3 antibodies are available:

The choice between monoclonal and polyclonal antibodies depends on your experimental needs:

• Monoclonal antibodies offer higher specificity and lot-to-lot consistency

• Polyclonal antibodies may provide stronger signals due to recognition of multiple epitopes

• For critical experiments, validation with two different antibodies (different host species or clones) is recommended

What are the common applications of PRMT3 antibodies in research?

PRMT3 antibodies are utilized in numerous techniques:

• Western Blot (WB): Detecting PRMT3 expression levels in cell/tissue lysates. Typical observed molecular weight is 70 kDa, although predicted size is 60 kDa .

• Immunoprecipitation (IP): Essential for studying PRMT3 interactions with binding partners and substrates. Critical in identifying novel PRMT3 substrates as seen in studies with METTL14, LDHA, IGF2BP1, and HSP60 .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Visualizing subcellular localization of PRMT3, typically showing cytoplasmic distribution .

• Immunohistochemistry (IHC): Evaluating PRMT3 expression in patient tissues, critical for clinical correlation studies .

• Sandwich ELISA: Quantitative measurement of PRMT3 levels using matched antibody pairs .

• ChIP Assays: Some specialized PRMT3 antibodies are suitable for chromatin immunoprecipitation to study epigenetic functions .

How should I optimize Western blot conditions for PRMT3 detection?

Based on published protocols:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors

  • Include methylation inhibitors (e.g., 20 mM sodium fluoride) to preserve methylation status

  • For detecting interaction partners, consider gentler lysis buffers

• Electrophoresis conditions:

  • 8-10% SDS-PAGE gels are recommended

  • Look for PRMT3 at approximately 70 kDa (observed) rather than the predicted 60 kDa

• Transfer and blocking:

  • PVDF membranes generally work better than nitrocellulose for PRMT3

  • Block with 5% non-fat milk or BSA in TBST

• Antibody dilutions and detection:

  • Primary antibody: 1:1000-1:2000 dilution (varies by manufacturer)

  • For ab191562: 1/40 dilution has been validated for IP-WB applications

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1/1500 dilution

  • ECL-based detection systems are generally sufficient

• Controls:

  • Include PRMT3 knockdown or knockout samples as negative controls

  • Consider using recombinant PRMT3 protein as a positive control

What are the best practices for immunoprecipitation when studying PRMT3 interactions and substrates?

IP protocols are critical for discovering novel PRMT3 substrates and interaction partners:

• Pre-clearing step:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use control IgG from the same species as your PRMT3 antibody

• IP conditions:

  • Use at least 500 μg of total protein for each IP reaction

  • Incubate with 2-5 μg antibody overnight at 4°C

  • Add protein A/G beads and incubate for 1-2 hours

  • For ab191562, 1/40 dilution has been validated for IP applications

• Wash conditions:

  • Use progressively stringent wash buffers to reduce background

  • Typically 4-5 washes are sufficient

• Elution methods:

  • Gentle elution with glycine buffer (pH 2.5) may preserve interactions

  • Direct boiling in SDS loading buffer is more efficient but disrupts interactions

• Special considerations for methylation studies:

  • Include methyl-group donors (SAM) and methylation inhibitors strategically

  • For validation of methylation sites, include R→K mutants as controls

What are the key considerations for immunofluorescence experiments with PRMT3 antibodies?

For optimal IF/ICC results:

• Fixation method:

  • 4% paraformaldehyde for 15 minutes at room temperature is standard

  • For some epitopes, methanol fixation may preserve antigenicity better

• Permeabilization:

  • 0.1-0.2% Triton X-100 in PBS for 10 minutes

  • For some applications, 0.5% saponin may provide better results

• Antibody dilutions:

  • For ab191562: 1/50 dilution has been validated

  • Secondary antibody: 1/200-1/400 dilution of fluorophore-conjugated antibodies

• Co-staining recommendations:

  • Include DAPI for nuclear staining

  • Consider co-staining with markers for specific cellular compartments to determine precise subcellular localization

• Controls:

  • Include negative controls (primary antibody omission)

  • Include PRMT3-depleted cells as biological negative controls

  • For colocalization studies, perform single staining controls

What are best practices for immunohistochemistry using PRMT3 antibodies in patient samples?

IHC optimization is crucial for clinical correlation studies:

• Antigen retrieval:

  • Heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 is recommended before IHC staining

  • Pressure cooker treatment (20 minutes) generally provides better results than microwave methods

• Blocking and antibody conditions:

  • Block endogenous peroxidase with 3% H₂O₂

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Primary antibody incubation: overnight at 4°C

  • Secondary antibody: 30-60 minutes at room temperature

• Scoring methods:

  • Develop a clear scoring system (e.g., 0-3 intensity scale)

  • Consider both staining intensity and percentage of positive cells

  • H-score method (combines intensity and percentage) is often used in PRMT3 studies

• Controls and validation:

  • Include known positive and negative tissue controls

  • Validate staining patterns with a second antibody to confirm specificity

  • Include isotype controls to rule out non-specific binding

How does PRMT3 contribute to cancer progression through substrate methylation?

PRMT3 methylates several key proteins involved in cancer progression:

• METTL14 methylation: PRMT3 interacts with and methylates METTL14 at arginine 418 (R418), promoting its degradation. This methylation downregulates GPX4 in an m6A-dependent manner, affecting ferroptosis susceptibility in endometrial cancer .

• LDHA methylation: PRMT3 interacts with and mediates asymmetric dimethylarginine (ADMA) modification of lactate dehydrogenase A (LDHA) at arginine 112 (R112). This increases LDH activity, promoting glycolysis and HCC growth .

• PDHK1 methylation: PRMT3 methylates pyruvate dehydrogenase kinase 1 (PDHK1) at arginine 363 and 368 residues, increasing its kinase activity and lactate production .

• IGF2BP1 methylation: PRMT3-mediated methylation of IGF2BP1 at R452 is critical for its function in stabilizing HEG1 mRNA, promoting oxaliplatin resistance in HCC .

• HSP60 methylation: PRMT3 methylates HSP60 at R446 to induce HSP60 oligomerization and maintain mitochondrial homeostasis, contributing to immunotherapy resistance in HCC .

These methylation events affect diverse cellular processes including metabolism, ferroptosis, and immune evasion, highlighting the multifaceted role of PRMT3 in cancer.

What is the role of PRMT3 in metabolic reprogramming in cancer cells?

PRMT3 functions as a key regulator of cancer metabolism:

• Glycolysis enhancement: PRMT3 promotes glycolysis in hepatocellular carcinoma by:

  • Methylating LDHA at R112, which increases LDH activity and lactate production

  • Enhancing the Warburg effect, converting glucose to lactate even in the presence of oxygen

• PDH pathway regulation: PRMT3 methylates PDHK1 at R363/368, increasing its kinase activity . This:

  • Inhibits pyruvate dehydrogenase (PDH) complex

  • Reduces pyruvate entry into the TCA cycle

  • Redirects pyruvate toward lactate production

• Lactate-mediated signaling: Increased lactate production by PRMT3:

  • Promotes histone lactylation (H3K18la)

  • Enhances PD-L1 expression through H3K18la binding to the PD-L1 promoter

  • Creates an immunosuppressive tumor microenvironment

• Ferroptosis resistance: PRMT3 indirectly regulates ferroptosis by:

  • Methylating METTL14, leading to its degradation

  • Reducing m6A modification of GPX4 mRNA

  • Stabilizing GPX4, a key ferroptosis regulator

This metabolic control positions PRMT3 as a potential therapeutic target for approaches that aim to reverse metabolic adaptations in cancer cells.

How is PRMT3 involved in immune evasion mechanisms in cancer?

PRMT3 contributes to immune evasion through multiple mechanisms:

• PD-L1 regulation: PRMT3 drives PD-L1-mediated immune escape by:

  • Activating lactate production through PDHK1 methylation

  • Promoting histone H3 lysine 18 lactylation (H3K18la)

  • Enhancing H3K18la binding to the PD-L1 promoter, increasing PD-L1 expression

• T cell exclusion: PRMT3 creates a T cell-poor tumor microenvironment:

  • Tissue analysis showed that high PRMT3 expression correlates with reduced CD8+ T cell infiltration

  • PRMT3 depletion increases T cell infiltration in HCC models

• cGAS/STING pathway modulation: PRMT3 suppresses anti-tumor immunity by:

  • Methylating HSP60 at R446

  • Inducing HSP60 oligomerization

  • Maintaining mitochondrial integrity

  • Preventing mitochondrial DNA leakage that would activate cGAS/STING signaling

• Response to immune checkpoint blockade: PRMT3 is induced by IFNγ-STAT1 signaling following ICB therapy:

  • This creates a negative feedback loop

  • Higher PRMT3 expression correlates with poorer response to ICB therapy

  • PRMT3 inhibition synergizes with PD-1 blockade in mouse models

These findings position PRMT3 as both a biomarker for immunotherapy response and a potential target for overcoming immunotherapy resistance.

What are the emerging roles of PRMT3 in therapeutic resistance?

PRMT3 contributes to various therapeutic resistance mechanisms:

• Oxaliplatin resistance in HCC:

  • PRMT3 methylates IGF2BP1 at R452

  • Methylated IGF2BP1 stabilizes HEG1 mRNA

  • This promotes oxaliplatin resistance through the PRMT3-IGF2BP1-HEG1 axis

  • PRMT3 overexpression may serve as a biomarker for oxaliplatin resistance

• Immune checkpoint blockade resistance:

  • PRMT3 expression is induced by ICB-activated T cells via IFNγ-STAT1 signaling

  • Higher PRMT3 levels correlate with reduced tumor-infiltrating CD8+ T cells

  • PRMT3 inhibition synergizes with PD-1 blockade in mouse models

• Ferroptosis resistance in endometrial cancer:

  • PRMT3 methylates METTL14, promoting its degradation

  • This leads to decreased m6A modification and stabilization of GPX4

  • GPX4 inhibits ferroptosis by reducing lipid peroxidation

  • PRMT3 inhibition sensitizes cells to ferroptosis and enhances efficacy of radiotherapy, chemotherapy, and immunotherapy

• Cell death evasion mechanisms:

  • PRMT3 deletion enhances the susceptibility of cancer cells to various death inducers

  • PRMT3 overexpression significantly decreased the proportion of cell death in multiple cancer models

These findings highlight PRMT3 as a potential biomarker for predicting treatment resistance and a promising target for combination therapies.

How do I interpret contradicting results in PRMT3 localization studies?

PRMT3 is primarily described as a cytoplasmic protein, but some studies report nuclear localization. Here's how to reconcile conflicting data:

• Technical considerations:

  • Fixation methods can alter apparent localization

  • Different antibodies may recognize different epitopes/isoforms

  • Overexpression systems may cause artifactual localization

• Biological explanations:

  • PRMT3 may shuttle between cytoplasm and nucleus under specific conditions

  • Post-translational modifications may affect localization

  • PRMT3 interactions with binding partners can influence subcellular distribution

• Methodological approach to resolve contradictions:

  • Use multiple antibodies recognizing different epitopes

  • Compare endogenous vs. tagged overexpression systems

  • Perform fractionation experiments with Western blot validation

  • Use live-cell imaging with fluorescently tagged PRMT3

  • Consider cell type-specific differences in localization

• Validation approaches:

  • CRISPR/Cas9 knockout followed by rescue with wildtype or mutant PRMT3

  • Co-staining with known nuclear and cytoplasmic markers

  • Biochemical fractionation followed by Western blotting

How can I determine if a protein is a direct PRMT3 substrate versus an indirect effect?

Distinguishing direct from indirect PRMT3 substrates requires multiple lines of evidence:

• Essential criteria for direct substrate confirmation:

  • Physical interaction (co-IP, BioID, or proximity labeling)

  • In vitro methylation assay with purified components

  • Identification of specific methylation site(s)

  • Decreased methylation upon PRMT3 knockout/inhibition

  • R→K mutation abolishes methylation

• Methodological approaches:

  • In vitro methylation assay: Incubate purified recombinant PRMT3 with candidate substrate and SAM (methyl donor)

  • Mass spectrometry analysis: Identify specific methylation sites

  • Methylation-specific antibodies: Detect ADMA modifications

  • Site-directed mutagenesis: Create R→K mutations at candidate sites

  • PRMT3 catalytic mutants: Use as negative controls

• Examples from literature:

  • METTL14: Confirmed direct substrate with R418 identified as methylation site

  • LDHA: Verified with R112 as the key methylation site

  • PDHK1: R363 and R368 identified as methylation sites

  • IGF2BP1: R452 confirmed as methylation site

  • HSP60: R446 identified as methylation site

• Controls and validation:

  • Catalytically inactive PRMT3 mutants as negative controls

  • Competitive inhibition with SAH or specific PRMT3 inhibitors (e.g., SGC707)

  • Substrate R→K mutants to verify specificity

  • Orthogonal methods to confirm findings

What are the most effective knockdown and knockout strategies for PRMT3 functional studies?

Various approaches for PRMT3 depletion have been used, each with advantages:

• RNAi-based approaches:

  • siRNA for transient knockdown (3-5 days)

  • shRNA for stable knockdown via lentiviral transduction

  • Multiple published sequences available with validated efficacy

  • Advantages: Simple, cost-effective, gradient of knockdown

  • Limitations: Incomplete knockdown, off-target effects

• CRISPR/Cas9 knockout strategies:

  • Complete elimination of PRMT3 expression

  • Multiple guide RNA sequences validated in publications

  • Can generate stable knockout cell lines

  • Advantages: Complete loss of function, stable phenotype

  • Limitations: Potential compensation, clone selection bias

• Conditional knockout systems:

  • Tet-inducible shRNA or CRISPR systems

  • Cre-loxP systems for tissue-specific deletion

  • Used successfully in mouse models

  • Advantages: Temporal and spatial control

  • Limitations: Leakiness, incomplete penetrance

• Pharmacological inhibition:

  • SGC707: Selective PRMT3 inhibitor used in multiple studies

  • Allows dose-dependent inhibition and temporal control

  • Advantages: Rapid, reversible, dose-titratable

  • Limitations: Potential off-target effects, incomplete inhibition

• Rescue experiments:

  • Critical for validating specificity

  • Use siRNA-resistant or gRNA-resistant PRMT3 constructs

  • Include wildtype and catalytically inactive mutants

  • Advantages: Controls for off-target effects

  • Used in multiple PRMT3 studies to confirm specificity

How should I interpret the discrepancy between PRMT3's predicted molecular weight (60 kDa) and observed Western blot size (68-70 kDa)?

The discrepancy between predicted (60 kDa) and observed (68-70 kDa) molecular weights for PRMT3 is consistent across studies and likely has biological explanations:

• Possible explanations:

  • Post-translational modifications (phosphorylation, methylation, etc.)

  • Alternative splicing producing larger isoforms

  • Intrinsic properties of the protein affecting migration

  • Technical aspects of SDS-PAGE systems

• Validation approaches:

  • Run recombinant PRMT3 protein as size control

  • Use PRMT3 knockout/knockdown samples as negative controls

  • Test multiple antibodies recognizing different epitopes

  • Perform mass spectrometry to identify modifications

• Technical considerations:

  • Different percentage gels may show slightly different migration patterns

  • Pre-stained markers can have their own variability

  • Different buffer systems may affect apparent molecular weight

• Documentation practices:

  • Always report both predicted and observed molecular weights

  • Include positive and negative controls in publications

  • Note the specific gel percentage and system used

  • Consider including a protein standard curve if precise sizing is critical

Notably, commercial antibody datasheets consistently report observed molecular weights of 68-70 kDa for PRMT3 , confirming this is a reproducible observation across different detection systems and not an experimental artifact.

What are the challenges in distinguishing type I PRMT activity (like PRMT3) from other PRMTs in cellular systems?

Distinguishing PRMT3 activity from other type I PRMTs presents several challenges:

• Overlapping substrate specificity:

  • Multiple PRMTs can methylate the same substrates

  • PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8 all catalyze asymmetric dimethylation

  • Consensus motifs show partial overlap

• Technical limitations:

  • Methylarginine antibodies don't distinguish which PRMT was responsible

  • Mass spectrometry identifies methylation sites but not the responsible enzyme

  • Inhibitors may have cross-reactivity with multiple PRMTs

• Methodological approaches to overcome these limitations:

  • Use PRMT3-specific knockdown/knockout models

  • Employ selective inhibitors (e.g., SGC707 for PRMT3)

  • Perform in vitro methylation with purified components

  • Utilize PRMT3 catalytic mutants as negative controls

  • Conduct simultaneous knockdown of multiple PRMTs

  • Identify PRMT3-specific interaction partners as likely substrates

• Substrate validation strategies:

  • Verify physical interaction with PRMT3

  • Test methylation in PRMT3-depleted cells

  • Confirm PRMT3 is sufficient using in vitro assays

  • Analyze methylation pattern differences

  • PRMT3 tends to prefer specific sequences identified through BioID technology

Understanding PRMT3-specific activity requires combining multiple approaches and careful controls to distinguish its function from other PRMTs.

What are the most promising therapeutic applications targeting PRMT3 in cancer?

Several therapeutic strategies targeting PRMT3 show promise:

These approaches highlight the potential of PRMT3 as both a therapeutic target and a biomarker for personalizing treatment strategies in cancer patients.

What emerging technologies are advancing PRMT3 research?

Several cutting-edge technologies are propelling PRMT3 research forward:

• Proximity labeling approaches:

  • BioID technology has expanded the known PRMT3 interactome

  • Identified 85 novel interacting proteins not previously reported in databases

  • Enables comprehensive substrate identification

• Mass spectrometry innovations:

  • Advanced proteomics to identify methylation sites with high sensitivity

  • Sequential window acquisition of all theoretical mass spectra (SWATH-MS)

  • Parallel reaction monitoring for targeted methylation analysis

• CRISPR-based screening methods:

  • CRISPR activation (CRISPRa) library screening identified PRMT3 as a key driver of oxaliplatin resistance

  • CRISPR knockout screens to identify synthetic lethal interactions with PRMT3

• Patient-derived models:

  • Patient-derived xenograft (PDX) models validated the importance of PRMT3 in treatment response

  • Organoid systems to study PRMT3 function in three-dimensional tissue context

• Computational approaches:

  • GPS-MSP analysis for predicting methylation sites (http://msp.biocuckoo.org/)

  • Systematic analysis of consensus motifs for PRMT3 substrates

  • Integration of multi-omics data to understand PRMT3 function in context

These technologies are accelerating the discovery of PRMT3 functions and therapeutic applications.

How does PRMT3 research integrate with the broader field of epitranscriptomics?

PRMT3 research intersects with epitranscriptomics in several important ways:

• PRMT3-METTL14 axis in m6A modification:

  • PRMT3 methylates METTL14 at R418, promoting its degradation

  • This decreases m6A RNA methylation of targets like GPX4

  • Demonstrates cross-talk between protein arginine methylation and RNA m6A methylation

• RNA binding protein regulation:

  • PRMT3 methylates RNA binding proteins like IGF2BP1

  • PRMT interactors are significantly enriched for RNA binding proteins involved in mRNA splicing and translation

  • This affects post-transcriptional gene regulation

• MicroRNA regulation:

  • PRMT family members influence miRNA expression and function

  • PRMT3 can affect miRNA pathways, though specific mechanisms need further investigation

• Translation regulation:

  • PRMT3 was originally identified as a ribosomal protein S2 binding partner

  • May influence translation efficiency through methylation of ribosomal components

• Technological integration:

  • RNA-protein crosslinking techniques like CLIP-seq can reveal how PRMT3-methylated RBPs interact with target RNAs

  • Ribosome profiling to study translational impacts of PRMT3

  • RNA structure probing to investigate how arginine methylation affects RNA binding